Clinical Trials

Inclusion Criteria:

• Age 15 and over (15+ will only occur in dental setting).
• English- or Spanish-speaking.
• Experiencing acute pain of less than 8 weeks duration at the time the opioid is prescribed.
• Received prescription for opioid analgesic at visit; opioids included in the study will be all FDA-approved enteral, transdermal, and transmucosal opioid analgesics including the most common: hydrocodone (except cough and anti-diarrheal medications), oxycodone, codeine (except cough medications), tramadol, morphine, hydromorphone.
  • We do not anticipate many opioid-naïve people receiving an opioid analgesic for acute pain will receive the following drugs, however, we will not exclude otherwise eligible patients who receive one of the following drugs: buprenorphine (as an analgesic), butorphanol, dihydrocodeine, fentanyl, meperidine, methadone (as an analgesic), oxymorphone, pentazocine, sufentanil, and tapentadol.
  • All of these opioids are included in any combinations with acetaminophen, aspirin, ibuprofen, naloxone, etc.
• Opioid naive (no use of prescribed opioids or illicit opioids, including medical or non-medical use, in the past 6 months) by self-report.
• Willing and able to give consent and participate in study.
• Able to access a mobile device (smartphone or tablet) with web access every day to complete study surveys.
• Willing to connect Fitbit to a device that can regularly link to Hugo for data transfer.
• Willing to use the health data sharing platform.
• Released/discharged to home after their visit.

Exclusion Criteria: 

• Pain thought to be caused by a systemic disease very likely to progress to chronic pain (e.g., sickle cell disease, fibromyalgia, lupus, multiple sclerosis, etc.).
• Cancer or end-of-life pain.
• Unable to give consent and be enrolled within 3 days of their visit.